Nobivac DP Plus
Authorised
This medicine is authorised for use in the European Union
Canine distemper vaccine (live, attenuated) and canine parvovirus vaccine (live, recombinant)
MedicineVeterinaryAuthorised
Overview
Nobivac DP Plus is a veterinary vaccine used to protect dogs against two separate infections caused by canine distemper virus and canine parvovirus.
Nobivac DP Plus contains the active substances live attenuated (weakened) canine distemper virus (CDV) and canine parvovirus (CPV).
The vaccine is given to puppies from four weeks of age as a single injection of 1 ml under the skin. It can only be obtained with a prescription.
Protection against canine distemper virus starts 7 days after vaccination, and protection against canine parvovirus infection starts 3 days after vaccination. Protection lasts for 8 weeks after vaccination.
For more information about using Nobivac DP Plus, see the package leaflet or contact your veterinarian or pharmacist.
Nobivac DP Plus is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. The canine distemper virus is alive, but it has been attenuated (weakened) so that it does not cause disease and the canine parvovirus component is a genetically modified hybrid strain. When Nobivac DP Plus is given to dogs, the animals’ immune system recognises the viruses as ‘foreign’ and makes antibodies against them. In the future, if the animals are exposed to these infections the immune system will be able to respond more quickly. This will help protect them against distemper and parvovirosis (infection caused by parvovirus).
Nobivac DP Plus was investigated in six laboratory studies and one field study, which showed that the vaccine was effective at preventing clinical signs of and death caused by CDV and CPV infection and preventing viral excretion following CDV and CPV infection. The studies also showed that immunity starts after 7 days for CDV and after 3 days for CPV and lasts for 8 weeks. One field study in 87 puppies showed that 91% of puppies had protective antibodies against CPV and 99% had protective antibodies against CDV after vaccination.
The most common side effect with Nobivac DP Plus (which may affect more than 1 in 10 animals) is a small, non-painful swelling (maximum 1 cm diameter) at the injection site observed within the first week after vaccination. The swelling will resolve completely within a few days.
For the full list of side effects and restrictions of with Nobivac DP Plus, see the package leaflet.
In case of accidental self-injection, medical advice should be sought immediately, and the package leaflet or label shown to the doctor.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Nobivac DP Plus’s benefits are greater than its risks and recommended that it can be approved for use in the EU.
Nobivac DP Plus received a marketing authorisation valid throughout the EU on 9 December 2020.
Product information
09/12/2020
Product details
- Name of medicine
- Nobivac DP Plus
- Active substance
- Live attenuated canine distemper virus strain Onderstepoort: 105.1 – 106.5 TCID50
- Live recombinant canine parvovirus strain 630a: 105.1 – 106.7 TCID50
- International non-proprietary name (INN) or common name
- Canine distemper vaccine (live, attenuated) and canine parvovirus vaccine (live, recombinant)
- Species
- Dogs (small)
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QI07AD03
Pharmacotherapeutic group
Immunologicals for canidaeTherapeutic indication
For the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.
News on Nobivac DP Plus
This page was last updated on